artificial intelligence
Group 42 and Oxford Nanopore Technologies have released details of a promising end-to-end solution that can mass screen for SARS-CoV-2.
The partnership aims to reduce pressure on the health system by automating the triage process.
insitro unveiled a $143 million Series B round on the same day that fellow machine learning company Exscientia highlighted its own $60 million Series C raise.
AI is steadily proving itself to the clinical community, but there are some aspects of care in which an algorithm will never be granted full control, said Cardiologs CEO Yann Fleureau.
Epstein Becker & Green's Bradley Merrill Thompson describes the agency's current trajectory for regulation of patient-facing and provider-facing telehealth products that incorporate AI.
SPONSORED
The advantages to health and human service delivery in a bot workforce include speed, reliability, consistency and cost-effectiveness. Sound too far-fetched for your management team? We would disagree.
The AI company now has a presence among more than 500 U.S. hospitals.
The recently announced COVID-19 Open Research Dataset consists of more than 29,000 machine-readable coronavirus articles ripe for analysis.
The collection of B2B AI companies already counts Concerto HealthAI among its numbers.
The system can complete a quantitative analysis of lung lesions in 2-3 seconds.